Neurocognitive dysfunction in the highly active antiretroviral therapy era

Current Opinion in Infectious Diseases

Volumn 25, Issue 1, 2012, Pages 4-9

  Mothobi, Nomvuyo Z ^a   Brew, Bruce J ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

Author keywords

Highly active antiretroviral therapy; HIV; HIV associated neurocognitive disorders; Neuro highly active antiretroviral therapy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

AGING; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; EARLY DIAGNOSIS; EARLY INTERVENTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; MULTIINFARCT DEMENTIA; NEUROTOXICITY; OUTCOME ASSESSMENT; PREVALENCE; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SCREENING; SUBSTANCE ABUSE; THERAPY EFFECT;

AGING; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HUMANS; PREVALENCE; RISK FACTORS;

EID: 84155171089     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834ef586     Document Type: Review

References (25)

1. Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17:1539-1545.
2. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
3. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre and post highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10:350-357.
4. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010; 75:2087-2096.
5. Brew BJ. Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis 2010; 50:930-932.
6. Brew BJ, Crowe SM, Landay A, et al. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2009; 4:163-174.
7. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV infected HAART treated patients. Neurology 2006; 66: 1447-1450.
8. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25:1747-1751.
9. Spudich S, Gisslen M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 2011; 204:753-760.
10. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73:342-348.
11. Brew BJ, Halman M, Catalan J, et al. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLos Clinical Trials 2007; 2:e13.
12. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999; 13:1889-1897.
13. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS clinical trials group. Ann Neurol 1993; 33:343-349.
14. Simioni S, CavassiniM, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243-1250.
15. Brew BJ, Cysique LA. Alzheimer disease and HIV: a tangled story. Neurology 2010; 75:105-106.
16. Cysique LA. Prevalence of nonconfounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011; 17:176-183.
17. Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50:920-929.
18. Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 2011; 76:693-700.
19. McManus H, Li P, Nolan D, et al. Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults? HIV Med 2011; 12:610-619.
20. Churchill MJ, Wesselingh SL, Cowley D, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009; 66:253-258.
21. Eugenin EA, Clements JE, Zink MC, Berman JW. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci 2011; 31:9456-9465.
22. Cysique LA, Maruff P, Bain MP, et al. HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci 2011; 23:83-89.
23. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010; 74:1260-1266.
24. Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75:864-873.
25. Cysique LA, Murray JM, Dunbar M, et al. A screening algorithm for HIV associated neurocognitive disorders. HIV Med 2010; 11:642-649.